share_log

康方生物-B:自願公告 - 依沃西(PD-1 /VEGF,AK112)聯合化療治療EGFR-TKI耐藥的EGFR突變的局部晚期或轉移性非鱗狀非小細胞肺癌(nsq-NSCLC)的III期臨床試驗完成受試者入組

AKESO, INC. - B: VOLUNTARY ANNOUNCEMENT - IVONESCIMAB (PD-1/VEGF, AK112) COMBINED WITH CHEMOTHERAPY FOR THE TREATMENT OF EGFR-MUTATED LOCALLY ADVANCED OR METASTATIC NSQ-NSCLC PATIENTS WHO HAVE FAILED TO EGFR-TKI TREATMENT COMPLETED PATIENT ENROLLMENT OF PH

Nov 3, 2022 18:26
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more